Literature DB >> 15171731

Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options.

Y Balash1, N Giladi.   

Abstract

The treatment of both generalized and focal dystonia is symptomatic. There is no evidence-based information about the efficacy of the different methods of the pharmacological therapeutic options currently being applied in dystonia. The specific questions addressed by this study were which treatments for dystonia have proven efficacy and which of them have unproven results. Following evidence-based principles, a literature review based on MEDLINE and the Cochrane Library, augmented by manual search of the most important journals was performed to identify the relevant publications issued between 1973 and 2003. All articles appearing in the professional English literature, including case reports, were considered. In the presence of comparable studies the meta-analysis was performed to obtain pooled information and make a reasonable inference. Based on this review, we conclude: (i) botulinum toxin has obvious benefit (level A, class I-II evidence) for the treatment of cervical dystonia and blepharospasm; (ii) trihexyphenidyl in high dosages is effective for the treatment of segmental and generalized dystonia in young patients (level A, class I-II evidence); (iii) all other methods of pharmacological intervention for generalized or focal dystonia, including botulinum toxin injections, have not been confirmed as being effective according to accepted evidence-based criteria (level U, class IV studies).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15171731     DOI: 10.1111/j.1468-1331.2004.00845.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  24 in total

1.  Selective inhibition of striatal fast-spiking interneurons causes dyskinesias.

Authors:  Aryn H Gittis; Daniel K Leventhal; Benjamin A Fensterheim; Jeffrey R Pettibone; Joshua D Berke; Anatol C Kreitzer
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

2.  Combination therapy for segmental craniocervical dystonia (Meige syndrome) with aripiprazole, trihexyphenidyl, and botulinum toxin: three cases reports.

Authors:  Tsukasa Saito; Takayuki Katayama; Jun Sawada; Kohei Kano; Asuka Asanome; Kae Takahashi; Nobuyuki Sato; Naoyuki Hasebe
Journal:  Neurol Sci       Date:  2014-08-24       Impact factor: 3.307

Review 3.  Diagnosis and treatment of dystonia.

Authors:  H A Jinnah; Stewart A Factor
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

4.  Functional activity of the sensorimotor cortex and cerebellum relates to cervical dystonia symptoms.

Authors:  Roxana G Burciu; Christopher W Hess; Stephen A Coombes; Edward Ofori; Priyank Shukla; Jae Woo Chung; Nikolaus R McFarland; Aparna Wagle Shukla; Michael S Okun; David E Vaillancourt
Journal:  Hum Brain Mapp       Date:  2017-06-08       Impact factor: 5.038

Review 5.  Medical and Surgical Treatments for Dystonia.

Authors:  H A Jinnah
Journal:  Neurol Clin       Date:  2020-03-02       Impact factor: 3.806

6.  Childhood dystonias.

Authors:  Samer D Tabbal
Journal:  Curr Treat Options Neurol       Date:  2015-03       Impact factor: 3.598

7.  Current and future medical treatment in primary dystonia.

Authors:  Cathérine C S Delnooz; Bart P C van de Warrenburg
Journal:  Ther Adv Neurol Disord       Date:  2012-07       Impact factor: 6.570

Review 8.  Task-specific dystonias: a review.

Authors:  Diego Torres-Russotto; Joel S Perlmutter
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 9.  Experimental therapeutics for dystonia.

Authors:  H A Jinnah; Ellen J Hess
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 10.  Update on pediatric dystonias: etiology, epidemiology, and management.

Authors:  Emilio Fernández-Alvarez; Nardo Nardocci
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.